做做功课,查查资料,然后才下结论。结果发现,自身免疫或授予免疫疗法对于非霍金淋巴瘤的研究和临床实验,并不是50年代用现在不用或不继续研究的疗法。近年都有大量有关这个的论文,研究和新的发现。
如:
Hematology Am Soc Hematol Educ Program. 2001:221-40.
Immunotherapy of Non-Hodgkin's lymphomas.
Press OW1, Leonard JP, Coiffier B, Levy R, Timmerman J.
Author information
Abstract
Recent years have witnessed the development of a variety of promising immunotherapies for treating patients with non-Hodgkin's lymphomas. Foremost among these advances is the exciting success of monoclonal antibodies directed against lymphocyte surface antigens. Rituximab is a chimeric (human-mouse) anti-CD20 antibody that induces responses in approximately half of the patients with relapsed indolent lymphomas and a third of patients with relapsed aggressive lymphomas when used as a single agent. Response rates appear even higher (up to 70%) for newly diagnosed patients treated with Rituximab monotherapy. Other promising antibodies for treatment of B cell malignancies include epratuzumab (anti-CD22), CAMPATH-1H (anti-CD52w), and Hu1D10 (anti-class II HLA). Even more exciting than antibody monotherapy is the prospect of combination antibody therapy (e.g. rituximab + epratuzumab) or combination chemotherapy and antibody therapy. In this regard, a recent phase III randomized trial from the GELA group in France demonstrated statistically significantly superior complete and overall response rates and superior event-free and overall survivals for elderly patients with newly diagnosed diffuse aggressive B cell lymphomas treated with CHOP + rituximab compared with CHOP alone. Confirmatory cooperative group trials combining chemotherapy with antibody therapies are currently underway. Another approach to augment the efficacy of antibodies is to deploy them in radiolabeled form. Iodine-131, Yttrium-90, and Copper-67 labeled monoclonal antibodies targeting CD-20, CD-22, HLA class II, and other cell surface antigens have been tested and demonstrate higher overall response rates (50-80%) and complete response rates (20-40%) than unlabeled antibodies. Pilot studies combining radiolabeled antibodies with either standard dose chemotherapy or myeloablative chemoradiotherapy with stem cell transplantation also appear very promising. Lymphoma vaccines have also produced very encouraging results in single institution studies at Stanford and the National Cancer Institute, with responding patients demonstrating superior event-free and overall survival than historical controls. Phase III randomized trials of idiotype vaccines are currently underway and novel new vaccine approaches are also being tested.
AND:
Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell
lymphoma using genetically modified autologous CD20-specific T cells
AND:
非霍奇金淋巴瘤进行常规疗法后,再利用生物免疫疗法,刺激机体的免疫细胞,全面激活和增强机体的免疫能力,恢复机体正常组织能力,达到彻底治愈癌症的目的。
非霍奇金淋巴瘤发病急,生长速度快,常伴有胸腔积液和气道阻塞,常使患者伴有气短、胸痛、咳嗽、疲劳不适、体重下降或上腔静脉综合征。也可使淋巴结遍布全身,此外,发病部位的淋巴结可出现无痛性肿大。由于部分淋巴结靠近神经、血管,因此晚期淋巴癌患者可累及多处脏器。那么,非霍奇金淋巴瘤应如何治疗呢?
1.手术治疗
肿瘤的手术治疗都是基于肉眼能够看到的病灶进行,在进行非霍奇金淋巴瘤手术切除的过程,对正常的血管、神经以及组织都会有所损害。且对残留隐藏在深处的非霍奇金淋巴瘤无法切除,容易造成患者功能区的损害,无形增大了手术的风险。
2.放射治疗
放射治疗作为辅助治疗,能延缓瘤复发和增加病人生存期。但放射治疗非霍奇金淋巴瘤有一定的禁忌症,并不是适合所有的非霍奇金淋巴瘤者,盲目的采用放射治疗,只能弊大于利,对患者造成更大的身心伤害。
3.化学治疗
通过化学药物对于人体细胞的无差别查杀,来达到治疗效果。但一并杀死了人体正常细胞 ,造成了机体免疫力的下降,结果往往得不偿失。
4.联合生物免疫综合疗法
国际肿瘤协会指出,想彻底杀死患者体内的肿瘤细胞,需从根源入手,近年来最新的生物免疫治疗就是利用了人体自身的免疫细胞,通过生物技术及生物剂千百倍的培养有利的免疫细胞,最后回输到患者体内,达到识别肿瘤并消灭的目的。
非霍奇金淋巴瘤进行常规疗法后,再利用生物免疫疗法,刺激机体的免疫细胞,全面激活和增强机体的免疫能力,恢复机体正常组织能力,达到彻底治愈癌症的目的。根据临床数据统计,针对早期患者使用生物免疫治疗可以达到根治的效果;对于中晚期患者,延长3到5年生存率达98.6%,延长5到10年生存率达76.5%。生物免疫治疗的到来,真正解决了癌细胞彻底杀死的难题,为广大患者治愈带来了希望。 |